Latest Content

10 of 500 Shown
  • Learning Module cme-icon ce-icon

    CCO Independent Conference Coverage: Clinical Impact of New Data From CROI 2017

    In this Expert Analysis, Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, provide an in-depth discussion of the most clinically relevant new data on the management of patients with HIV infection presented at CROI 2017.
    Faculty: Joel E. Gallant MD, MPH, Charles B. Hicks MD
    Released: 4/27/2017
  • CT2 (Coming soon)

    Charles B. Hicks MD -
  • Contemporary Management of HIV: New Data From CROI 2017

    In this downloadable slideset, Charles B. Hicks, MD, and Program Director Joseph J. Eron, Jr., MD, review key new HIV data presented at the Seattle 2017 meeting.

    Topics include:
    -Prevention
    -New data on currently available ART
    -Switch/simplification strategies for virologically suppressed patients
    -Investigational ARV agents
    -Treatment complications and comorbidities
    Date Posted: 4/26/2017
  • Contemporary Management of HIV: Management of HIV in Women

    In this downloadable slideset, Kathleen E. Squires, MD, and Program Director Joseph J. Eron, Jr., MD, review key data and optimal strategies in caring for HIV-infected women, including ART safety and efficacy in women, reproductive health management, ART and pregnancy, and preventing HIV infection in women.
    Date Posted: 4/25/2017
  • Contemporary Management of HIV: Management of Aging Patients

    In this downloadable slideset, Edgar Turner Overton, MD, and Program Director Joseph J. Eron, Jr., MD, review key data on managing aging patients with HIV.
    Date Posted: 4/24/2017
  • How New Data From CROI 2017 May Inform Switch Strategies in HIV-Infected Patients With Poor Bone Health

    Charles B. Hicks MD - 4/21/2017
    Is switching TDF to TAF justified in osteopenic women?
  • How New Data From CROI 2017 May Renew Interest in NNRTIs

    Charles B. Hicks MD - 4/21/2017
    How do phase III data on doravirine affect the potential for future therapy with NNRTIs?
  • Optimal ART During Late Pregnancy After a Break in Therapy

    Kathleen E. Squires MD - 4/20/2017
    Which regimen may work best during the third trimester?
  • How New Data From CROI 2017 May Inform Treatment Simplification Options

    Charles B. Hicks MD - 4/20/2017
    Is the switch to a 2-drug regimen in virologically suppressed HIV-infected patients feasible?
  • The Promise of Long-Acting Injectable Antiretroviral Therapies

    Paul E. Sax MD - 4/12/2017
    Will long-acting cabotegravir plus rilpivirine injections satisfy patient desire for less frequent dosing? Here is my take.
10 of 500 Shown
Show 10 More
Loading...  
Decision Support
Free
inPractice
Immediate answers to treatment questions
More than just up to date